Shéhérazade Sebda

<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Houria Debarri, Delphine Lebon, Christophe Roumier et al. · Oncotarget · 2015 · 98 citations · Full text

Medicine, Hematology, Oncology +15

<i>TP53</i> Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

Stéphanie Poulain, Christophe Roumier, Elisabeth Bertrand et al. · Clinical Cancer Research · 2017 · 96 citations

Medicine, Genetics, Molecular Genetics +17

Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease

Émilie Faivre, Joana E. Coelho, Katja Zornbach et al. · Frontiers in Molecular Neuroscience · 2018 · 89 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

Noémie Leblay, Frédéric Leprêtre, Nolwenn Le Stang et al. · Journal of Thoracic Oncology · 2016 · 86 citations

Medicine, Cancer Biology, Oncology +15

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

Jean‐Emmanuel Bibault, Martin Figeac, Nathalie Hélevaut et al. · Oncotarget · 2015 · 56 citations · Full text

Life Sciences, Genetics, Hematology +17